I am a nuclear medicine physician with extensive and broad experience in clinical nuclear medicine. I have been practicing nuclear medicine for several years and have been involved in the day-to-day clinical use of radiopharmaceuticals for diagnosis and therapy; and in conducting and interpreting SPECT/CT, PET/CT, and nuclear cardiology studies. I am particularly interested in molecular imaging with PET/CT and in developing novel techniques to diagnose and treat cancer, particularly breast and gynecologic malignancies.
My focus is radiopharmaceutical therapy, and I am studying the use radiolabeled monoclonal antibodies to detect and treat cancers. These include: radiolabeled antibodies 8H9 and 3F8 for pediatric cancers such as metastatic neuroblastoma and brain tumors; radioimmunoPET imaging and radioimmunotherapy for renal cancer, prostate cancer, ovarian cancer, pancreatic cancer, lymphoma, and colon cancer; and the use of peptides in diagnosing and treating neuroendocrine tumors. I am also studying the use of alpha emitters in treating bone metastasis and alpha-emitter-conjugated radiolabeled antibodies in the treatment of other malignancies. I routinely perform radiopharmaceutical therapy with 131I-MIBG for neuroendocrine tumors including neuroblastoma, pheochromocytoma, and paraganglioma; bexxar and zevalin therapy for lymphoma; and strontium or samarium radionuclides to treat metastatic bone disease pain.
I also serve as Director of the Nuclear Medicine Training Program.